These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9408077)

  • 21. Determinants of Gli2 co-activation of wildtype and naturally truncated androgen receptors.
    Li N; Chen M; Truong S; Yan C; Buttyan R
    Prostate; 2014 Oct; 74(14):1400-10. PubMed ID: 25132524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Poly (A) Binding Protein Cytoplasmic 1 Is a Novel Co-Regulator of the Androgen Receptor.
    Eisermann K; Dar JA; Dong J; Wang D; Masoodi KZ; Wang Z
    PLoS One; 2015; 10(7):e0128495. PubMed ID: 26176602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of glucocorticoid and androgen receptor gene fusions delineates domains required for transcriptional specificity.
    Whitacre DC; Karnas KJ; Miesfeld RL
    Endocrine; 2001 Jun; 15(1):111-8. PubMed ID: 11572317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Supervillin associates with androgen receptor and modulates its transcriptional activity.
    Ting HJ; Yeh S; Nishimura K; Chang C
    Proc Natl Acad Sci U S A; 2002 Jan; 99(2):661-6. PubMed ID: 11792840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains.
    Wong CI; Zhou ZX; Sar M; Wilson EM
    J Biol Chem; 1993 Sep; 268(25):19004-12. PubMed ID: 8360187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation.
    Ikonen T; Palvimo JJ; Kallio PJ; Reinikainen P; Jänne OA
    Endocrinology; 1994 Oct; 135(4):1359-66. PubMed ID: 7925097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impaired helix 12 dynamics due to proline 892 substitutions in the androgen receptor are associated with complete androgen insensitivity.
    Elhaji YA; Stoica I; Dennis S; Purisima EO; Lumbroso R; Beitel LK; Trifiro MA
    Hum Mol Genet; 2006 Mar; 15(6):921-31. PubMed ID: 16449235
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions.
    Yang CS; Xin HW; Kelley JB; Spencer A; Brautigan DL; Paschal BM
    Mol Cell Biol; 2007 May; 27(9):3390-404. PubMed ID: 17325038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation.
    Wong HY; Hoogerbrugge JW; Pang KL; van Leeuwen M; van Royen ME; Molier M; Berrevoets CA; Dooijes D; Dubbink HJ; van de Wijngaart DJ; Wolffenbuttel KP; Trapman J; Kleijer WJ; Drop SL; Grootegoed JA; Brinkmann AO
    Mol Cell Endocrinol; 2008 Sep; 292(1-2):69-78. PubMed ID: 18656523
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions.
    Duff J; McEwan IJ
    Mol Endocrinol; 2005 Dec; 19(12):2943-54. PubMed ID: 16081517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences.
    Zhou ZX; Sar M; Simental JA; Lane MV; Wilson EM
    J Biol Chem; 1994 May; 269(18):13115-23. PubMed ID: 8175737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The hinge region in androgen receptor control.
    Clinckemalie L; Vanderschueren D; Boonen S; Claessens F
    Mol Cell Endocrinol; 2012 Jul; 358(1):1-8. PubMed ID: 22406839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel mutation in the human androgen receptor suggests a regulatory role for the hinge region in amino-terminal and carboxy-terminal interactions.
    Deeb A; Jääskeläinen J; Dattani M; Whitaker HC; Costigan C; Hughes IA
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3691-6. PubMed ID: 18697867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions between androgen and estrogen receptors and the effects on their transactivational properties.
    Panet-Raymond V; Gottlieb B; Beitel LK; Pinsky L; Trifiro MA
    Mol Cell Endocrinol; 2000 Sep; 167(1-2):139-50. PubMed ID: 11000528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function.
    Buchanan G; Yang M; Harris JM; Nahm HS; Han G; Moore N; Bentel JM; Matusik RJ; Horsfall DJ; Marshall VR; Greenberg NM; Tilley WD
    Mol Endocrinol; 2001 Jan; 15(1):46-56. PubMed ID: 11145738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of the interaction between androgen receptor and a new transcriptional inhibitor, SHP.
    Gobinet J; Auzou G; Nicolas JC; Sultan C; Jalaguier S
    Biochemistry; 2001 Dec; 40(50):15369-77. PubMed ID: 11735420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization.
    Jenster G; van der Korput HA; van Vroonhoven C; van der Kwast TH; Trapman J; Brinkmann AO
    Mol Endocrinol; 1991 Oct; 5(10):1396-404. PubMed ID: 1775129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor.
    Carsol JL; Gingras S; Simard J
    Mol Endocrinol; 2002 Jul; 16(7):1696-710. PubMed ID: 12089361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity.
    James AJ; Agoulnik IU; Harris JM; Buchanan G; Tilley WD; Marcelli M; Lamb DJ; Weigel NL
    Mol Endocrinol; 2002 Dec; 16(12):2692-705. PubMed ID: 12456791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptor ligand-binding domain interaction and nuclear receptor specificity of FXXLF and LXXLL motifs as determined by L/F swapping.
    Dubbink HJ; Hersmus R; Pike AC; Molier M; Brinkmann AO; Jenster G; Trapman J
    Mol Endocrinol; 2006 Aug; 20(8):1742-55. PubMed ID: 16627595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.